BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy
نویسندگان
چکیده
منابع مشابه
BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
BRAF inhibitor (BRAFi) has been used for treatment of melanomas harboring V600E mutation. Despite a high initial response rate, resistance to BRAFi is inevitable. Here, we demonstrate that BRAFi-resistant (BR) melanomas are susceptible to arginine deprivation due to inability to initiate re-expression of argininosuccinate synthetase (ASS1, a key enzyme for arginine synthesis) as well as ineffec...
متن کاملPhosphoproteomic Analysis of Cell-Based Resistance to BRAF Inhibitor Therapy in Melanoma
The treatment of melanoma by targeted inhibition of the mutated kinase BRAF with small molecules only temporarily suppresses metastatic disease. In the face of chemical inhibition tumor plasticity, both innate and adaptive, promotes survival through the biochemical and genetic reconfiguration of cellular pathways that can engage proliferative and migratory systems. To investigate this process, ...
متن کاملRegarding BRAF-inhibitor therapy of primary ameloblastoma.
To the Editor: Tan et al. describe the use of dabrafenib in the management of a primary intraosseous BRAF V600E mutant ameloblastoma prior composite surgical resection, as a single case report. Although this potentially represents a novel approach to management for some cases of ameloblastoma, inclusion of several additional data points would be instructive. At initial presentation, the 4-cm ma...
متن کاملBRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospects.
BRAF is a major oncoprotein and oncogenic mutations in BRAF are found in a significant number of cancers, including melanoma, thyroid cancer, colorectal cancer and others. Consequently, BRAF inhibitors have been developed as treatment options for cancers with BRAF mutations which have shown some success in improving patient outcomes in clinical trials. Development of resistance to BRAF kinase i...
متن کاملAcquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.
BRAF inhibitors elicit rapid antitumor responses in the majority of patients with BRAF(V600)-mutant melanoma, but acquired drug resistance is almost universal. We sought to identify the core resistance pathways and the extent of tumor heterogeneity during disease progression. We show that mitogen-activated protein kinase reactivation mechanisms were detected among 70% of disease-progressive tis...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pigment Cell & Melanoma Research
سال: 2017
ISSN: 1755-1471
DOI: 10.1111/pcmr.12674